Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults

被引：192

作者：

Kasamon, Yvette L. ^{[1
]}

Bolanos-Meade, Javier ^{[1
]}

Prince, Gabrielle T. ^{[1
]}

Tsai, Hua-Ling ^{[1
]}

McCurdy, Shannon R. ^{[1
]}

Kanakry, Jennifer A. ^{[1
]}

Rosner, Gary L. ^{[1
]}

Brodsky, Robert A. ^{[1
]}

Perica, Karlo ^{[1
]}

Smith, B. Douglas ^{[1
]}

Gladstone, Douglas E. ^{[1
]}

Swinnen, Lode J. ^{[1
]}

Showel, Margaret M. ^{[1
]}

Matsui, William H. ^{[1
]}

Huff, Carol Ann ^{[1
]}

Borrello, Ivan ^{[1
]}

Pratz, Keith W. ^{[1
]}

McDevitt, Michael A. ^{[1
]}

Gojo, Ivana ^{[1
]}

Dezern, Amy E. ^{[1
]}

Shanbhag, Satish ^{[1
]}

Levis, Mark J. ^{[1
]}

Luznik, Leo ^{[1
]}

Ambinder, Richard F. ^{[1
]}

Fuchs, Ephraim J. ^{[1
]}

Jones, Richard J. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Baltimore, MD USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 28期

基金：

美国国家卫生研究院;

关键词：

STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; UMBILICAL-CORD BLOOD; VERSUS-HOST-DISEASE; BONE-MARROW; HEMATOLOGIC MALIGNANCIES; REDUCED-INTENSITY; IDENTICAL SIBLINGS; MYELODYSPLASTIC SYNDROME; RESPONSE CRITERIA;

D O I：

10.1200/JCO.2014.60.4777

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Recent advances in nonmyeloablative (NMA), related HLA-haploidentical blood or marrow transplantation (haplo-BMT) have expanded the donor pool. This study evaluated the effect of age on NMA haplo-BMT outcomes in patients age 50 to 75 years. Patients and Methods A retrospective analysis was performed of 271 consecutive patients with hematologic malignancies, age 50 to 75 years, who received NMA, T-cell-replete haplo-BMT with high-dose post-transplantation cyclophosphamide. Results The median age was 61 years, with 115 patients (42%) age 50 to 59, 129 (48%) age 60 to 69, and 27 (10%) age 70 to 75 years. Overall, 84% of patients had intermediate- or high-/very high-risk disease. The 6-month probabilities of grade 3 or 4 acute graft-versus-host disease (GVHD) and nonrelapse mortality (NRM) were 3% and 8%, respectively. Patients in their 50s, 60s, and 70s had 6-month NRM probabilities of 8%, 9%, and 7%, respectively (P = .20). With a median follow-up of 4 years, corresponding 3-year progression-free survival probabilities were 39%, 35%, and 33% (P = .65), and corresponding 3-year overall survival probabilities were 48%, 45%, and 44% (P = .66). Three-year progression-free survival probabilities were 40% in acute myeloid leukemia (n = 65), 39% in aggressive non-Hodgkin lymphoma (n = 83), and 37% in indolent or mantle-cell lymphoma (n = 65). Older patient age was associated with a significantly higher risk of grade 2 to 4 acute GVHD but not grade 3 to 4 acute or chronic GVHD. No statistically significant associations were found between older age (relative to age 50 to 59 years or as a continuous variable) and NRM, relapse, or survival. Conclusion NMA haplo-BMT with post-transplantation cyclophosphamide has encouraging safety and survival outcomes in patients age 50 to 75 years. In patients otherwise fit for BMT, the results support consideration of this approach despite advanced age. (C) 2015 by American Society of Clinical Oncology

引用

页码：3152 / +

页数：12

共 42 条

[1] Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age [J].

Alyea, EP ;

Kim, HT ;

Ho, V ;

Cutler, C ;

Gribben, J ;

DeAngelo, DJ ;

Lee, SJ ;

Windawi, S ;

Ritz, J ;

Stone, RM ;

Antin, JH ;

Soiffer, RJ .

BLOOD, 2005, 105 (04) :1810-1814

[2]

[Anonymous], SEER stat fact sheets

[3] Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT) [J].

Aoudjhane, M ;

Labopin, M ;

Gorin, NC ;

Shimoni, A ;

Ruutu, T ;

Kolb, HJ ;

Frassoni, F ;

Boiron, JM ;

Yin, JL ;

Finke, J ;

Shouten, H ;

Blaise, D ;

Falda, M ;

Fauser, AA ;

Esteve, J ;

Polge, E ;

Slavin, S ;

Niederwieser, D ;

Nagler, A ;

Rocha, V .

LEUKEMIA, 2005, 19 (12) :2304-2312

[4] Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation [J].

Armand, Philippe ;

Kim, Haesook T. ;

Logan, Brent R. ;

Wang, Zhiwei ;

Alyea, Edwin P. ;

Kalaycio, Matt E. ;

Maziarz, Richard T. ;

Antin, Joseph H. ;

Soiffer, Robert J. ;

Weisdorf, Daniel J. ;

Rizzo, J. Douglas ;

Horowitz, Mary M. ;

Saber, Wael .

BLOOD, 2014, 123 (23) :3664-3671

[5] MARROW TRANSPLANTATION FROM RELATED DONORS OTHER THAN HLA-IDENTICAL SIBLINGS [J].

BEATTY, PG ;

CLIFT, RA ;

MICKELSON, EM ;

NISPEROS, BB ;

FLOURNOY, N ;

MARTIN, PJ ;

SANDERS, JE ;

STEWART, P ;

BUCKNER, CD ;

STORB, R ;

THOMAS, ED ;

HANSEN, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (13) :765-771

[6] Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts [J].

Brunstein, Claudio G. ;

Fuchs, Ephraim J. ;

Carter, Shelly L. ;

Karanes, Chatchada ;

Costa, Luciano J. ;

Wu, Juan ;

Devine, Steven M. ;

Wingard, John R. ;

Aljitawi, Omar S. ;

Cutler, Corey S. ;

Jagasia, Madan H. ;

Ballen, Karen K. ;

Eapen, Mary ;

O'Donnell, Paul V. .

BLOOD, 2011, 118 (02) :282-288

[7]

Center for International Blood and Marrow Transplant Research, 2014, CIBMTR FORMS MAN 100

[8] Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia [J].

Chen, Yi-Bin ;

Li, Shuli ;

Lane, Andrew A. ;

Connolly, Christine ;

Del Rio, Candice ;

Valles, Betsy ;

Curtis, Morgan ;

Ballen, Karen ;

Cutler, Corey ;

Dey, Bimalangshu R. ;

El-Jawahri, Areej ;

Fathi, Amir T. ;

Ho, Vincent T. ;

Joyce, Amy ;

McAfee, Steven ;

Rudek, Michelle ;

Rajkhowa, Trivikram ;

Verselis, Sigitas ;

Antin, Joseph H. ;

Spitzer, Thomas R. ;

Levis, Mark ;

Soiffer, Robert .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (12) :2042-2048

[9] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[10] Revised response criteria for malignant lymphoma [J].

Cheson, Bruce D. ;

Pfistner, Beate ;

Juweid, Malik E. ;

Gascoyne, Randy D. ;

Specht, Lena ;

Horning, Sandra J. ;

Coiffier, Bertrand ;

Fisher, Richard I. ;

Hagenbeek, Anton ;

Zucca, Emanuele ;

Rosen, Steven T. ;

Stroobants, Sigrid ;

Lister, T. Andrew ;

Hoppe, Richard T. ;

Dreyling, Martin ;

Tobinai, Kensei ;

Vose, Julie M. ;

Connors, Joseph M. ;

Federico, Massimo ;

Diehl, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586

← 1 2 3 4 5 →